UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience

The oncologist (Dayton, Ohio), 2017-02, Vol.22 (2), p.144-151

2017

Volltextzugriff (PDF)

Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection

Pharmacotherapy, 2016-12, Vol.36 (12), p.1245-1254

2016

Volltextzugriff (PDF)

Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory

Pharmacotherapy, 2017-09, Vol.37 (9), p.1014-1022

2017

Volltextzugriff (PDF)

Evaluation of pharmacy students' knowledge and perceptions of pharmacogenetics before and after a simulation activity

Currents in pharmacy teaching and learning, 2018-01, Vol.10 (1), p.96-101

2018

Volltextzugriff (PDF)

Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned

Clinical and translational science, 2018-03, Vol.11 (2), p.175-181

2018

Volltextzugriff (PDF)

Hospitalization-Associated Change in Gait Speed and Risk of Functional Limitations for Older Adults

The journals of gerontology. Series A, Biological sciences and medical sciences, 2019-10, Vol.74 (10), p.1657-1663

2019

Volltextzugriff (PDF)

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

The New England journal of medicine, 2022-01, Vol.386 (4), p.316-326

2022

Volltextzugriff (PDF)

Understanding the implementation and sustainability needs of evidence-based programs for racial and ethnic minoritized older adults in under-resourced communities with limited aging services

BMC health services research, 2024-04, Vol.24 (1), p.466-466, Article 466

2024

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes

Clinical pharmacology and therapeutics, 2019-06, Vol.105 (6), p.1338-1344

2019

Volltextzugriff (PDF)

Sleep Disturbances and Risk of Hospitalization and Inpatient Days Among Older Women

Sleep (New York, N.Y.), 2017-04, Vol.40 (4)

2017

Volltextzugriff (PDF)

Abstract PO-192: Comparing the association of self-reported race-ethnicity and genetic ancestry with all-cause mortality: A pan-cancer survivor analysis in the PLCO Screening Trial

Cancer epidemiology, biomarkers & prevention, 2022-01, Vol.31 (1_Supplement), p.PO-192-PO-192

2022

Volltextzugriff (PDF)

Abstract 4090: Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4090-4090

2017

Volltextzugriff (PDF)

Abstract 2721: Discovery and development of orally available subnanomolar potent checkpoint kinase 1 inhibitors as potential anticancer therapies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2721-2721

2016

Volltextzugriff (PDF)

Silk Genes Support the Single Origin of Orb Webs

Science (American Association for the Advancement of Science), 2006-06, Vol.312 (5781), p.1762-1762

2006

Volltextzugriff (PDF)

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study

mAbs, 2011-05, Vol.3 (3), p.289-298

2011

Volltextzugriff (PDF)

Abstract 297: The novel orally available sub-nanomolar potent and selective checkpoint kinase 1 inhibitor CASC-578 is highly active in mantle cell lymphoma as a single agent and in combination with Wee1 inhibition

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.297-297

2017

Volltextzugriff (PDF)

Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial

JAMA ophthalmology, 2021-12, Vol.139 (12), p.1266

2021

Volltextzugriff (PDF)

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma

Nature communications, 2022-03, Vol.13 (1), p.1100-1100, Article 1100

2022

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S Genotypes

Clinical pharmacology and therapeutics, 2019-06, Vol.105 (6), p.1338-1344

2019

Volltextzugriff (PDF)

Abstract 295: CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.295-295

2017

Volltextzugriff (PDF)

Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options

Current treatment options in cardiovascular medicine, 2016-05, Vol.18 (5), p.33, Article 33

2016

Volltextzugriff (PDF)

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study

Blood advances, 2022-12, Vol.6 (23), p.6005-6015

2022

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience

Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection

Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory

Evaluation of pharmacy students' knowledge and perceptions of pharmacogenetics before and after a simulation activity

Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned

Hospitalization-Associated Change in Gait Speed and Risk of Functional Limitations for Older Adults

CATARACTS: Challenge on automatic tool annotation for cataRACT surgery

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Understanding the implementation and sustainability needs of evidence-based programs for racial and ethnic minoritized older adults in under-resourced communities with limited aging services

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes

Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial

G‐quadruplex‐binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo

Sleep Disturbances and Risk of Hospitalization and Inpatient Days Among Older Women

Abstract PO-192: Comparing the association of self-reported race-ethnicity and genetic ancestry with all-cause mortality: A pan-cancer survivor analysis in the PLCO Screening Trial

Abstract 4090: Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor

Abstract 2721: Discovery and development of orally available subnanomolar potent checkpoint kinase 1 inhibitors as potential anticancer therapies

Silk Genes Support the Single Origin of Orb Webs

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study

Abstract 297: The novel orally available sub-nanomolar potent and selective checkpoint kinase 1 inhibitor CASC-578 is highly active in mantle cell lymphoma as a single agent and in combination with Wee1 inhibition

Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma

Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR 1 or CACNA 1S Genotypes

Abstract 295: CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition

Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study

Suchergebnisse filtern